The bladder cancer market has seen a tremendous uptake of immune checkpoint inhibitors with their approval in the locally advanced / metastatic setting and, in the case of Merck & Co.’s Keytruda, BCG-unresponsive non-muscle-invasive disease. These therapies have significantly altered the treatment landscape for bladder cancer, particularly among the cisplatin-ineligible population. Notably, the entry of two novel agents for previously treated locally advanced or metastatic disease, Janssen’s first-in-class FGFR inhibitor Balversa (erdafitinib) for patients harboring susceptible FGFR genetic alterations, and Astellas / Seattle Genetics’ ADC Padcev (enfortumab vedotin-ejfv), further expands U.S. physicians’ armamentarium beyond standard treatment options.
- What percentage of non-muscle-invasive bladder cancer patients receive maintenance BCG therapy, and how does this percentage vary by stage and histologic grade?
- What is the uptake of immune checkpoint inhibitors in the United States across therapy lines? How are immune checkpoint inhibitors faring against older (e.g., platinum-based chemotherapy) and/or newer therapies (e.g., Balversa, Padcev)?
- How do drug-treatment rates vary across key patient populations and treatment lines?
- What are the main drivers of and obstacles to the treatment with key drugs for unresectable locally advanced or metastatic bladder cancer?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
- Bladder Cancer - Current Treatment - Detailed, Expanded Analysis: Physician Insights (US)
- Current Treatment Physician Insights Bladder Cancer US June 2020
Author(s): Liseth Parra; Grace Mitchell, M.Res
Liseth M Parra, Ph.D., is an analyst on the Oncology team at Decision Resources Group with an extensive background in oncology research and market analysis. Prior to joining DRG, Liseth generated valuable offerings and comprehensive strategic solutions for leading R&D clinical, commercial, and marketing teams in oncology as a research analyst for Kantar Health and as an independent consultant. Liseth holds a Ph.D. in neurobiology from the University of California, San Diego and completed a postdoctoral fellowship in oncology at the Brigham and Women’s Hospital, Harvard Medical School. Liseth supports DRG’s syndicated oncology research offerings, focusing on malignant melanoma disease landscape and forecast analysis.
is a business insights analyst in the oncology team at Decision Resources Group. Ms. Mitchell previously worked as an analyst at financial PR firm, Tulchan Communications, where she provided news on the pharmaceutical sector from a commercial perspective. Prior to this, Ms. Mitchell was a project assistant within the consulting team at DRG-Abacus where she learnt about HEOR and market access. Ms. Mitchell obtained her Masters in Cancer Sciences from the University of Birmingham. The degree focused on the expression of immune checkpoints in DLBCL. She also holds a B.Sc. in Biomedical Science from the University of Reading.